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ABSTRACT 
After encounter with central nervous system (CNS)- derived autoantigen, lymphocytes leave 
the lymph nodes and enter the CNS. This event leads only rarely to subsequent tissue 
damage. Genes relevant in CNS- infiltrating cells leading to subsequent CNS pathology are 
largely undefined. Myelin-oligodendrocyte-glycoprotein (MOG)- induced experimental 
autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS), a 
chronic autoimmune disease of the central nervous system (CNS), resulting in disability. To 
assess genes which are involved in encephalitogenicity and subsequent tissue damage 
mediated by CNS infiltrating cells we performed a DNA microarray analysis from cells 
derived from lymph nodes and eluted from CNS in LEW.1AV1 (RT1av1) rats immunized 
with MOG 91-108. The data was compared to immunizations with adjuvant alone or naïve 
rats and to immunizations with the immunogenic but not encephalitogenic MOG 73-90 
peptide. Here we show involvement of Cd38, Cxcr4 and Akt and confirm these findings 
employing CD38 knock-out (B6.129P2-Cd38tm1Lnd/J) mice, S1P-receptor modulation during 
EAE and quantitative expression analysis in patients with MS. The hereby defined underlying 
pathways indicate cellular activation and migration pathways mediated by G-protein coupled 
receptors as critical events in CNS tissue damage. These pathways can be further explored for 
novel therapeutic interventions. 
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INTRODUCTION 
Multiple sclerosis (MS) is a disease of the central nervous system (CNS) which leads to 
chronic inflammation, demyelination, axonal and neuronal loss resulting in disability 
(Noseworthy et al., 2000, Weissert, 2013). Myelin-oligodendrocyte-glycoprotein (MOG)- 
induced experimental autoimmune encephalomyelitis (EAE) in rats reproduces major aspects 
of the human pathology (Weissert et al., 1998b, Storch et al., 1998, Kornek et al., 2000, 
Weissert, 2016). MOG is expressed on the outer surface of the myelin sheath. In contrast to 
merely T cell-mediated animal models, the pathogenesis of MOG-induced EAE in the rat 
involves the combined action of T and B cells, antibodies as well as macrophages, mimicking 
type II lesions in MS (Genain et al., 1995, Mathey et al., 2004, Lucchinetti et al., 2000).  
Encephalitogenic peptides presented on MHC class II molecules to T cells lead to a program 
which forces lymphocytes to be activated and migrate towards the CNS (Riedhammer and 
Weissert, 2015). Adjuvant contributes by affecting multiple signalling pathways in 
lymphocytes as well as in organ resident cells like the CNS. We have previously 
demonstrated that MOG 91-108 is the major determinant to trigger disease in rats expressing 
RT1av1 or RT1n haplotypes (Weissert et al., 2001). Interestingly, the capacity of MOG 91-108 
to induce EAE was dissociated in regard to Th1 or Th2 cytokine expression in lymphoid 
tissue compared to CNS. Moreover, different MOG 1-125- derived peptides, such as MOG 
73-90, were immunogenic showing strong Th1 responses but were not encephalitogenic. The 
induction of active EAE in LEW MHC congenic rat strains and DA (RT1av1) rats does not 
require the application of pertussis toxin like in mice. This is an advantage since the exact 
role of pertussis toxin in EAE induction is not clear so far. Pertussis toxin inhibits Gi proteins 
and influences by this multiple cellular processes and pathways (Dumas et al., 2014). Active 
EAE in susceptible rat strains is induced by immunization with an encephalitogenic peptide 
mixed with mineral oil (incomplete Freund’s adjuvant) with the addition of heat-inactivated 
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mycobacterium tuberculosis (MT) as adjuvant (complete Freund’s adjuvant). MT leads by 
binding and signalling through Toll-like receptors (TLR) to an activation program in a 
number of cell types and is also a systemic ‘danger signal’ (Mills, 2011). 
In regard to susceptibility to EAE and MS gene expression profiling studies were performed 
to elucidate genes which are involved in disease pathogenesis. A number of interesting genes 
were described like osteopontin (Hur et al., 2007). In no study a systematic comparison of 
gene expression profiles was performed in EAE in which the influence of adjuvant and 
antigen was systematically compared on the expression profile of lymph node derived cells or 
cells eluted from CNS of diseased animals. In this study we systematically compared the 
gene expression profiles of cells from draining lymph nodes and CNS infiltrating cells which 
were eluted in LEW.1AV1 (RT1av1) rats immunized with MOG91-108 in CFA, CFA alone 
and naïve rats. Moreover we compared the gene expression profile of rats immunized with 
the encephalitogenic MOG peptide 91-108 with rats immunized with the non-
encephalitogenic MOG peptide 73-90. We found differentially expressed genes which are of 
major importance for encephalitogenicity. The influence of these genes was subsequently 
verified by different means.  
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RESULTS 
Gene expression after immunization with encephalitogenic and non-encephalitogenic 
peptides 
One of the important questions in MS and other inflammatory diseases of the CNS is to 
understand the requisites of autoantigenic peptides to induce CNS inflammation 
(Riedhammer and Weissert, 2015). Beside presentation of autoantigen-derived peptides on 
MHC molecules and the availability of reactive T cell and B cell repertoires as well as the 
presence of the target antigen in the CNS, pathways of cellular activation exist that allow 
disease development. These pathways are presently only partly elucidated. We used MOG-
induced EAE in LEW.1AV1 (RT1av1) rats as a model system for CNS inflammation. In this 
EAE model the determinant MOG 91-108 is immunogenic and encephalitogenic. In contrast 
the determinant MOG 73-90 is immunogenic but not encephalitogenic. We assessed the gene 
expression profiles by gene arrays of lymphocytes from draining lymph nodes and from 
lymphocytes eluted from the CNS.  
To focus on genes which are truly relevant to encephalitogenicity and not simply involved in 
general inflammatory responses, we compared gene arrays of LEW.1AV1 (RT1av1) rats 
immunized with the encephalitogenic MOG stretch MOG 91-108 to naïve LEW.1AV1 
(RT1av1) rats and rats immunized with the adjuvant CFA alone as well as rats immunized 
with the non-encephalitogenic MOG 73-90 determinant. We analyzed ten comparisons for 
each of the naïve and CFA groups versus MOG 91-108 and five comparisons for MOG 73-90 
versus MOG 91-108. The number of comparisons in which a given gene had a signal log 
ratio (SLR) of above 1 were counted. In table 1, we show genes which are upregulated in at 
least half of the comparisons (=50%). Besides Cxcr4 and Cd38, which were subsequently 
analysed in greater detail, many genes with a known function in EAE and MS pathology were 
found to have an increased expression in MOG 91-108 immunized rats as compared to 
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controls. This validates our gene list and supports the relevance of the genes not previously 
described in EAE. In table S1, genes with decreased expression in EAE are listed. In this 
analysis, the variability between gene arrays was much higher and less genes were found to 
be regulated with a clear pattern according to our criteria.  
Comparisons of microarrays of CNS-infiltrating lymphocytes derived from LEW.1AV1 
(RT1av1) rats after immunization with MOG 91-108, MOG 73-90 and CFA alone resulted in 
many more genes being differentially expressed as compared to the analysis of lymph node 
cells (Table S2 and Table S3). This could mirror the influx of different cell populations into 
the CNS during an inflammatory attack. Similar to the analysis of lymph node cells we found 
that Cd38 and Cxcr4 mRNA was strongly increased in CNS-infiltrating cells.  
Subsequently, we analysed purified CD4+ cells from lymph nodes and CNS of MOG 91-108 
and MOG 73-90 immunized rats. To some extent similar gene expression profiles were found 
in the purified CD4+ cell population compared to non-separated lymph node cells (Table 1, 
Table S4, Table S5).  
Due to their strong expression in MOG 91-108-immunized rats compared to naïve, CFA-
immunized and MOG 73-90-immunized rats, we chose Cxcr4 and Cd38 for further analysis.  
 
Cxcr4 and Cd38 in EAE in LEW.1AV1 (RT1av1) rats 
Confirming our microarray results by quantitative PCR we found a significant upregulation 
of Cxcr4 expression in lymph node cells of MOG 91-108-immunized rats (n=8) as compared 
to CFA-immunized (n=8, ANOVA, P<0.0001) and naïve (n=6, ANOVA, P<0.0001) 
LEW.1AV1 (RT1av1) rats (Fig. 1A). Also an increased expression of Cd38 was measured 
(MOG 91-108-immunized rats [n=8] as compared to CFA-immunized [n=8, ANOVA, 
P<0.05] and naïve [n=6, ANOVA, P<0.05] LEW.1AV1 [RT1av1] rats).  
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In cells eluted from CNS we found upregulation of Cxcr4 (Fig. 1B) and CD38 (Fig. 1C) in 
MOG 91-108 immunized LEW.1AV1 (RT1av1) rats (n=6) compared to rats immunized with 
MOG 73-90 (n=6, ANOVA Cxcr4 and Cd38 each P<0.001) or CFA alone (n=6, ANOVA, 
Cxcr4 and Cd38 each P<0.001).  
 
Cxcr4 and Cxcl12 expression in spinal cord of DA (RT1av1) rats 
Next we assessed the mRNA expression of Cxcr4 (Fig. 2A) and its ligand Cxcl12 (Fig. 2B) in 
spinal cord of either naïve DA (RT1av1) rats or DA (RT1av1) rats immunized with IFA or CFA 
alone or MOG 1-125 in IFA or MOG 1-125 in CFA (each n=4). Upregulation of both Cxcl12 
and Cxcr4 mRNA expression was observed in CFA and MOG 1-125 in CFA immunized DA 
(RT1av1) rats in spinal cord compared to naïve rats, IFA injected or MOG 1-125 in IFA 
immunized DA (RT1av1) rats (ANOVA, P<0.001). Increased Cxcl12 and Cxcr4 mRNA 
expression was observed in MOG 1-125 in CFA compared to CFA immunized DA (RT1av1) 
rats (ANOVA, P<0.01). 
 
Cxcr4 and CXCL12 in patients with MS 
Upregulation of mRNA of Cxcr4 was also observed in white blood cells of MS patients with 
a relapsing-remitting disease course (RRMS, n=32) and a secondary chronic progressive 
disease course (SPMS, n=22) compared to controls (n=25, ANOVA for RRMS and SPMS 
each P<0.05) (Fig. 3A, Table S6, Table S7). Also, we detected increased protein CXCL-12 
serum levels in both patients with RRMS (n=24) and SPMS (n=28) compared to controls 
(n=21, ANOVA for RRMS and SPMS each P<0.05) (Fig. 3B, Table S6, Table S7).  
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EAE in B6.129P2-Cd38tm1Lnd/J mice 
Cd38 was strongly upregulated in encephalitogenic lymph node cells. To functionally 
validate our data and to elucidate the role of CD38 in EAE, we induced disease with the 
extracellular domain of MOG (MOG 1-125) in CD38 knock out (B6.129P2-Cd38tm1Lnd/J) 
mice and appropriate controls. We found reduced disease severity in MOG 1-125-immunized 
B6.129P2-Cd38tm1Lnd/J mice (n=22) compared to wild type control mice (n=21, t-test, 
cumulative disease score P<0.01) (Fig. 4A). Next we determined the height of the antibody 
response to MOG 1-125. Reduced anti-MOG IgG autoantibody responses in B6.129P2-
Cd38tm1Lnd/J mice (n=4) compared to wild type control mice (n=4, ANOVA, P<0.05)) after 
immunization with MOG 1-125 were seen (Fig. 4B) on day 12 p.i. Furthermore, also T cell 
responses upon restimulation with MOG 1-125 were reduced in the B6.129P2-Cd38tm1Lnd/J 
mice (n=4) on day 12 p.i. compared to control mice (n=4, t-test for stimulation with 50µg/ml 
MOG 1-125, P<0.05) as measured in a proliferation assay indicating in addition a T cell 
priming or expansion defect in B6.129P2-Cd38tm1Lnd/J mice (Fig. 4C).  
 
Targeting cellular migration by FTY720 
We found an upregulation of Akt in our differential gene expression studies (Table 1). 
FTY720 is a S1P-receptor modulator known to influence T cell trafficking by an Akt- 
dependent mechanism, as does CXCR4 (Mandala et al., 2002, Cyster, 2005, Lee et al., 2001, 
Brinkmann et al., 2002, Matloubian et al., 2004). We evaluated inhibition of Akt-dependent 
cell trafficking in MOG 91-108-immunized LEW.1AV1 (RT1av1) rats. Disease was 
completely inhibited in rats treated from day 0 p.i. with FTY720  (n=10) as compared to the 
vehicle treated controls (n=10, t-test, cumulative disease score P<0.0001) (Fig. 5A). Next, we 
tested the efficacy of FTY720 to treat established relapsing-remitting MOG 1-125-induced 
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EAE in the DA (RT1av1) rat. FTY720 treatment was started on day 21 p.i., after the first bout 
of disease (n=8), and showed a significant effect on the disease course as compared to vehicle 
treatment (n=8, t-test, cumulative disease score day 21-44 p.i., P<0.01) (Fig. 5B). To further 
examine the beneficial effect of FTY720 treatment on EAE, we boosted the rats with MOG 
1-125 on day 44 after the first immunization. Although a relapse was induced in both groups, 
the DA rats under FTY720 treatment had a better clinical outcome compared to the vehicle 
treated animals (t-test, cumulative disease score day 45-56 p.i. P<0.0001). On day 14 p.i. 
FTY720 treatment led to an increase of the relative size of the CD4 T cell compartment 
(ANOVA, P<0.01) in the treated LEW.1AV1 (RT1av1) rats (n=10) compared to controls 
(n=9) concurrent with a decrease in the CD8 T cell (ANOVA, P<0.01) and the B cell 
(ANOVA, P<0.01) compartment (Fig. 5C; Fig. S1). FTY720 treatment (n=9) compared to 
controls (n=9) led to down-regulation of mRNA expression of its receptor S1p1 (ANOVA, 
P<0.0001) and of Akt2 (ANOVA, P<0.0001), one of the genes involved in the intracellular 
signalling cascade connected to S1P1 and CXCR4 on day 14 p.i. Treatment also had a 
negative effect on the expression levels of Cd38, (ANOVA, P<0.0001). In contrast, the 
expression of Cxcr4 was not altered (ANOVA, not significant) (Fig. 5D).  
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DISCUSSION 
In this study we identified gene networks that are critically involved not only in raising an 
autoantigen- specific immune response but also constituting encephalitogenicity. We 
analysed the expression and functional relevance of genes and their products expressed on 
lymphocytes after immunization with the encephalitogenic MOG91-108 peptide in adjuvant, 
the non-encephalitogenic MOG73-90 peptide in adjuvant, adjuvant alone or naïve rats. Most 
interestingly in the comparison of MOG91-108 in adjuvant to MOG73-90 in adjuvant 
immunized rats, compared to the other analyses, only a small number of genes were 
differentially expressed. These genes seem to be of major importance since they are genes 
involved in the encephalitogenic response leading to disease manifestation. From the overall 
expression data, we selected three genes which were upregulated in many comparison: Cxcr4, 
Cd38 and Akt. We performed functional studies regarding these genes in EAE and analysed 
tissue samples from MS patients.  
CXCR4 (CD184) is a seven transmembrane G-coupled receptor expressed by a number of 
tissues including cells of the immune system (Campbell et al., 2003). CXCR4 knock-out mice 
die in utero or perinatally and do not only have defects in the hematopoietic system 
(impairment of myeloid and B cell generation, reduced proliferation of triple-negative and 
double-positive lymphocytes), but also in the circulatory system and in the CNS (Zou et al., 
1998, Tachibana et al., 1998). Overexpression of CXCR4 on T cells induces their 
accumulation in the bone marrow and reduction of these cells in the peripheral blood. 
CXCR4 signalling leads to a prolonged protein kinase B (AKT) and extracellular signal-
regulated kinase 2 activation in T cells. AKT activation promotes cell survival and can act as 
costimulation for T cell activation (Tilton et al., 2000). CXCR4 has only one known cognate 
ligand which is CXCL12. CXCL12 is constitutively produced by stromal and endothelial 
cells. CXCL12 activates numerous signalling pathways like receptor-associated trimeric G 
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proteins, phospholipase C, PI3K and small G proteins (Pawig et al., 2015). Signalling 
through these receptors leads to an increase in the intracellular calcium concentration, 
cytoskeleton reorganization and cellular migration. Several modulating factors such as 
phosphatases, regulator of G-protein signalling, adaptor proteins and ubiquitin may affect 
signalling and/or chemotactic response of CXCR4 to its ligand. An important function of 
CXCR4/CXCL12 is the regulation of bone-marrow homeostasis and lymphocyte trafficking. 
Chemotaxis and integrin-mediated adhesion are the main cellular responses to CXCL12. 
CXCL12 knock-out mice display the same phenotype as CXCR4 knock-out mice (Nagasawa 
et al., 1996).  
In autoimmunity there are indications that the interaction of CXCR4 and CXCL12 could be 
important. CXCL12 recruits B cells to inflamed glomeruli in which these cells my produce 
autoantibodies (Balabanian et al., 2003). Also in rheumatoid arthritis CXCR4 and CXCL12 
have been proposed to be important in the disease precipitation (Zhang et al., 2005). A role of 
CXCR4 and CXCL12 in EAE (Meiron et al., 2008, Kohler et al., 2008, McCandless et al., 
2006) as well as in MS has been described (Azin et al., 2012, Krumbholz et al., 2006). 
Our data indicates that also in MOG-induced EAE and possibly MS the interaction of 
CXCR4 and CXCL12 is of paramount importance for disease development. We found 
specific upregulation of Cxcr4 on cells derived from lymph nodes and eluted from CNS of 
rats immunized with encephalitogenic MOG91-108 peptide in comparison to controls. In 
addition, we measured upregulation of Cxcl12 and Cxcr4 in spinal cords in EAE compared to 
controls. CXCL12 is upregulated in the CNS of MS patients (Krumbholz et al. 2006 and own 
unpublished observations). Together the presented data would argue for a scenario in which 
lymphnode- derived cells are in the context of an encounter with an encephalitogenic antigen 
activated and migrate towards CXCL12 in the CNS. This is further underscored by the fact 
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that nitric oxide enhances LPS-induced expression of CXCR4 and migration towards 
CXCL12 (Giordano et al., 2006).  
CD38 is a membrane associated type II glycoprotein which acts both as an receptor and 
enzyme (Cockayne et al., 1998, Kato et al., 1999, Salmi and Jalkanen, 2005). As an enzyme it 
catalyzes NAD+ into cyclic ADP-ribose and further into ADP-ribose. It also regulates Ca2+ 
levels from ryanodine receptor stores. CD38 is expressed on a variety of myeloid and 
lymphoid cells. CD38 ligation in B cells leads to tyrosine phosphorylation of several 
intracellular proteins such as Syk, p85 of phophatidylinositol-3 kinase and phospholipase C- 
(Silvennoinen et al., 1996). CD38 ligation in T cells results in phosphorylation of the Raf-
1/MAP kinase and CD3-/ZAP-70 signalling pathway (Zubiaur et al., 1997). Furthermore it 
is involved in dendritic cell migration and adhesion between lymphocytes and endothelial 
cells (Partida-Sanchez et al., 2004). B6.129P2-Cd38tm1Lnd/J mice show slight reduction of 
antibody titers to T cell-dependent antigens (Cockayne et al., 1998). Additionally, these mice 
had increased susceptibility to bacterial infections, which is thought to be caused by a 
defective chemotactic response of neutrophils towards bacteria underscoring a role in innate 
immunity as well (Partida-Sanchez et al., 2001).  
We induced EAE in CD38 knock out mice (B6.129P2-Cd38tm1Lnd/J) and controls. CD38 
knock out mice had a reduced disease severity and lower autoantibody and T cell responses 
as compared to the controls. These finding show the importance of CD38 in EAE and 
possibly MS. This work lies the basis for further analysis of the involved cellular 
compartments and regulation of human disease (Mayo et al., 2008, Lischke et al., 2013). 
FTY720 is a potent drug that affects lymphocyte trafficking and homing. Our studies and 
studies by others (Brinkmann et al., 2002, Balatoni et al., 2007) showed a strong beneficial 
effect of FTY720 on EAE under various experimental settings. The drug was approved for 
treatment of MS (Kappos et al., 2010). We demonstrate that treatment of MOG-EAE with 
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FTY720 impacts the gene expression of the genes that are involved in encephalitogenic 
immune responses. This further validates our approach. We measured changes in expression 
of S1P1, Akt2 and Cd38. Interestingly, no changes in expression of Cxcr4 was observed. The 
reason for this is not fully understood and deserves further investigations. 
In conclusion in this study we have identified genes which are involved not only in raising an 
autoantigen-specific immune responses but constitute encephalitogenicity. The immunization 
with encephalitogenic peptides induces a network of genes involved in activation and 
migration of lymphocytes. Based on this platform we have established the paramount 
importance of G-coupled proteins in encephalitogenicity of adaptive immune responses. We 
speculate that similar involvement might operate also in other autoimmune diseases and 
possibly transplant rejection thereby establishing common mechanisms. These pathways 
might be valuable targets of therapeutic approaches as we have shown attenuation of EAE 
after treatment with FTY720 or reduced EAE severity in CD38-deficient mice. These 
findings not only validate our gene expression data, but also underscore the importance of the 
rat EAE model in translational medicine. 
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MATERIALS AND METHODS 
Animals and EAE induction 
Female rats or mice, 10-14 weeks of age, were used in all experiments. LEW.1AV1 (RT1av1) 
rats were obtained from Hans Hedrich (Central Animal Laboratory, Hannover Medical 
School, Hannover, Germany) and DA (RT1av1) rats were obtained from Harlan Winkelmann 
(Borchen, Germany). Female B6.129P2-CD38tm1Lnd/J mice and the appropriate controls 
C57BL/6J 000664 were purchased from the Jackson Laboratory (Bar Harbor, USA). 
Animals were bred and kept under specific pathogen-free conditions. Animals were injected 
intradermally at the base of the tail (rats) or both flanks (mice) with 100 µg of MOG 91–108 
(rats) or 50 µg of rat recombinant MOG 1-125 (rats) or 100 µg MOG 35-55 (mice) or 20 µg 
rat recombinant MOG 1-125 (mice). The antigens in a total volume of 100 µl were mixed 
with 100 µl of CFA (1:1). A total of 100 µl of CFA consisted of IFA (Sigma-Aldrich, St. 
Louis, MO) and 500 µg for rats or 400 µg for mice of heat-inactivated Mycobacterium 
tuberculosis (strain H37 RA; Difco Laboratories, Detroit, MI) (Weissert, 2016). Mice 
additionally received 100 ng of pertussis toxin (Calbiochem, Darmstadt, Germany) on day 0 
and 2 intraveniously. Some groups of rats were also injected with 100 µl IFA mixed with 100 
µl MOG 1-125 in PBS (50 µg) without the addition of Mycobacterium tuberculosis or with 
IFA or CFA alone. The clinical scoring was as follows: 0 = no illness; 1 = tail weakness or 
paralysis; 2 = hind leg paraparesis or hemiparesis; 3 = hind leg paralysis or hemiparalysis; 4 = 
tetraparesis or moribund. All experiments were approved by the regional board in Tübingen, 
Germany. 
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Human samples 
Blood samples were obtained after consent from patients with MS and controls. The 
characteristics of the MS patients and controls are indicated in Table S6 and Table S7. The 
research was approved by the Ethics committee of the University of Tuebingen in Germany 
(Permission 125/2001). 
 
Isolation of CNS infiltrating cells 
Infiltrating cells from the CNS were prepared as described before (Weissert et al., 1998a, 
Weissert et al., 2001). In brief, rats were perfused with cold PBS, and brains and spinal cords 
were dissected out on day 12 p.i. Subsequently, brains and spinal cords were homogenized in 
10 ml 50% Percoll/0.1% BSA/1% glucose (Amersham Pharmacia Biotech) containing 500 U 
DNase type I (Life Technologies). Ten ml of 50% Percoll were added to each sample after 
homogenization. A discontinuous Percoll gradient was obtained by adding seven ml of 63% 
Percoll below and 20 ml of 30% Percoll above the sample. Samples were centrifuged for 40 
min at 1000 x g at 4°C. Lymphocytes were collected from the 63/50% Percoll interface. The 
cells were subsequently washed twice in 15–25 ml PBS with centrifugation at 600 x g for 15 
min at 4°C.  
 
Isolation of mononuclear cells (MNC) from lymph nodes (LN) and spleens 
Draining inguinal LN and spleens were dissected out under deep anaesthesia. LN were 
disrupted and MNC washed twice in Dulbecco’s modified eagle medium (DMEM, Life 
Technologies, Paisley, U.K.), resuspended in complete medium (CM) containing DMEM 
supplemented with 5% fetal calf serum (PAA Laboratories Linz, Austria), 1% 
penicillin/streptomycin (Life Technologies), 1% glutamine (Life Technologies), and 50 µM 
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2-mercaptoethanol (Life Technologies) and flushed through a 70-µm plastic strainer (Falcon; 
BD Biosciences, Franklin Lakes, NJ). MNC from spleen were prepared in the same way as 
from LN with the difference that red blood cells (RBC) were lysed with lysis buffer 
consisting of 0.15 M NH4Cl, 10 mM KHCO3, and 0.1 mM Na2 EDTA adjusted to pH 7.4. 
CD4+ cells were isolated by anti- rat CD4 microbeads using MACS technology (Miltenyi 
Biotech, Bergisch Gladbach, Germany) according to the manufacturers instruction. 
 
CD4+ cell purification 
CD4+ cells from the lymph nodes were purified by MACS (Miltenyi Biotech, Bergisch 
Gladbach, Germany) and subsequently analyzed by Affymetrix gene array for differential 
gene expression. 
 
Spinal cord tissue 
From PBS- perfused naïve or in either IFA, CFA, MOG 1-125 in IFA or MOG 1-125 in CFA 
DA immunized rats, spinal cord tissues was dissected and homogenized and subsequently 
assessed for mRNA expression. 
 
RNA preparation 
Total RNA of brain infiltrating leukocytes or lymphocytes or spinal cord tissue was isolated 
by using a RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. The RNA quality was analysed with a Bioanalyser 2100 (Agilent, Palo Alto, 
USA).  
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Microarrays  
Affymetrix microarrays of the type RG U34 A (Affymetrix Inc., Santa Clara, USA) 
representing approximately 7000 full length genes and 1000 EST clusters were used. For the 
purified CD4+ cells the rat expression set 230A (Affymetrix) containing about 30.000 
features was used. For each array, samples from at least three rats were pooled. Biotin 
labelled cRNA was prepared and hybridized to the arrays. In brief, double stranded cDNA 
was synthesized from whole RNA using a superscript choice kit (Invitrogen) with a T7-
(dT)24 primer (Metabion) and in vitro transcribed into biotin-labelled cRNA. After 
hybridization gene arrays were washed and stained by a fluidics station (Affymetrix) and 
scanned by a confocal laser scanning microscope (Agilent). 
The data was analyzed using the microarray suite software, micro DB, and data mining tool 
(Affymetrix). Only genes and EST were included in further analysis which were “present” 
and gave a difference call of either “increase” or “decrease” according to the Affymetrix 
software. The extend of differential expression is expressed as signal log ratio (SLR). For the 
tables the cut off was set to a SLR of 1 signifying an 2-fold change in expression. Doubles, 
ESTs, and sequences not corresponding to a gene were not included in the tables. 
 
Real time PCR 
To avoid amplification/detection of contaminating genomic DNA, extracted RNA was treated 
with Rnase free DNase (Promega, Madison, WI). Subsequently, cDNA was synthesized by 
reverse transcription with Moloney murine leukemia virus reverse transcriptase and random 
pdN6 primers in the presence of RNase inhibitor (Promega). Amplification was performed on 
an Applied Biosystems Prism 7000 Sequence Detection System (Applied Biosystems, Foster 
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City, CA) using a SYBR green protocol. Results were expressed as 2- CT values. The 
primer sequences 5´ to 3´ were as follows:  
 
Rat primers 
Gapdh:   forward: GGTTGTCTCCTGTGACTTCAA 
       reverse: CATACCAGGAAATGAGCTTCAC 
S1p1:   forward: TAGCCGCAGCAAATCAGAC 
   reverse: GCAGCAGTGGAGAAAGAGAGA 
Cxcr4:   forward: GATGGTGGTGTTCCAGTTCC 
   reverse: CAGCTTGGAGATGATGATGC 
Cxcl12:   forward: CGATTCTTTGAGAGCCATGT 
reverse: AGGGCACAGTTTGGAGTGTT 
Cd38:   forward: AGGACACACTGCTGGGCTAT 
   reverse: CAGGGTTGTTGGGACAATTT 
Akt2:   forward: GAAGACTGAGAGGCCACGAC 
   reverse: GGGAGCCACACTTGTAATCC 
 
Human primers 
h18s:    forward: CGGCTACCACATCCAAGGAA 
reverse: GCTGGAATTACCGCGGCT 
Cxcr4:   forward: CATCAGTCTGGACCGCTACC,  
reverse: GGATCCAGACGCCAACATAG. 
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FACS 
FITC conjugated mAb against CD45RA (OX-33) and TCRAB (R73) and PE conjugated 
mAb against CD4 (OX-35) and MHC II (OX-6) and appropriate isotype controls were 
purchased from Becton Dickinson (Heidelberg, Germany). Flow cytometry was performed on 
a FACScalibur running with Cellquest software (Becton Dickinson). Cells were gated on the 
lymphocyte population in the FSC-SSC dot plot. For data analysis also Flowing Software 
2.5.1 (Turku Center for Biotechnology, Finland) was used. 
 
ELISA  
Serum taken at the time point of euthanasia was subject to an anti-MOG autoantibody 
ELISA. ELISA plates (96 well; Nunc, Roskilde, Denmark) were coated with 2.5 µg/ml (100 
µl/well) MOG 1-125 overnight at 4°C. Plates were washed with PBS/0.05% Tween 20 and 
blocked with milk powder for 1 h at room temperature. After washing, diluted serum samples 
were added and plates were incubated for 1 h at room temperature. Then, plates were washed 
and rabbit anti mouse antiserum (IgG, IgG1, IgG2a, IgG2b, IgG3, IgM Nordic, Tilburg, The 
Netherlands) was added and incubated for 1 h at room temperature. Plates were washed prior 
to the addition of peroxidase conjugated goat anti rabbit antiserum (Nordic) diluted in 
PBS/0.05% Tween 20. After 30 min incubation, plates were washed and bound Abs were 
visualized by addition of ABTS (Roche Diagnostics Mannheim, Germany). After 15 minutes 
of incubation optical density was read at 405 nm. 
ELISA with human serum was performed according to the instructions of the manufacturer. 
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Proliferation assay 
Cells from draining LN were prepared as described above and cultured in the presence of 
rrMOG in 96 well plates as described in the Elispot section. Cells were cultured for 48h and 
pulsed with 1µCi [3H]thymidine for the last 18 h. The incorporation of [3H]thymidine was 
measured using a beta-scintillation counter. 
 
FTY720 treatment 
Rats were treated with FTY720 (generous gift of Novartis AG, Switzerland) and received a 
daily dose of 0,4 mg/kg in sterile water by oral gavage as described (Balatoni et al., 2007). 
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Fig. 1. Cxcr4 and Cd38 expression in lymph node cells and CNS.  
A, Quantitative SYBR green real time PCR was performed for Cxcr4 and Cd38 in lymph 
node cells from naïve (black bars, n=6), CFA (grey bars, n=8) or MOG 91-108 in CFA (white 
bars, n=8)- immunized LEW.1AV1 (RT1av1) rats on day 12 p.i.. Increased Cxcr4 (*ANOVA, 
P<0.0001) and Cd38 (*ANOVA, P<0.05) expression was found in MOG 91-108 in CFA- 
immunized rats compared to naïve and CFA- alone- immunized rats. B, Quantitative 
expression of Cxcr4 in cells eluted from CNS of CFA (white bars, n=6), MOG 73-90 in CFA 
(grey bars, n=6) and MOG 91-108 in CFA (n=6) immunized LEW.1AV1 (RT1av1) rats. 
Cxcr4 was upregulated in MOG 91-108 in CFA-immunized rats compared to the other 
groups (*ANOVA, P<0.001) on day 12 p.i.. C, Quantitative expression of Cd38 of 
lymphocytes eluted from CNS of CFA (white bars, n=6), MOG 73-90 in CFA (grey bars, 
n=6) and MOG 91-108 in CFA (n=6) immunized LEW.1AV1 (RT1av1) rats on day 12 p.i. 
Cd38 was upregulated in MOG 91-108 in CFA-immunized rats compared to the other groups 
(*ANOVA, P<0.001). Results are expressed as 2-ΔΔ CT values. Numbers are mean +/- SEM. 
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Fig 2. Cxr4 and Cxcl12 expression in spinal cord of DA (RT1av1) rats. 
Quantitative SYBR green real time PCR was performed for Cxcr4 (A) and Cxcl12 (B) from 
PBS- perfused spinal cord tissue of naïve DA (RT1av1) rats (n=4), rats immunized with IFA 
(n=4) or CFA alone (n=4) and DA rats immunized with MOG 1-125 in IFA (n=4) or MOG 1-
125 in CFA (n=4) on day 12 p.i. Increased Cxcr4 and Cxcl12 expression was observed in 
spinal cord in DA (RT1av1) rats immunized with CFA and MOG1-125 in CFA (*ANOVA, 
P<0.001). There was an upregulation of Cxcr4 and Cxcl12 mRNA in DA (RT1av1) rats 
immunized with MOG 1-125 in CFA compared to DA (RT1av1) rats immunized with CFA 
alone (*ANOVA, P<0.01). Quantitative PCR results are expressed as 2-ΔΔ CT values. 
Numbers are mean +/- SEM. 
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Fig. 3. Cxcr4 expression in white blood cells and CXCL12 protein in serum of patients 
with MS.  
A, Cxcr4 mRNA was quantified by real time PCR from white blood cells of patients with 
relapsing remitting MS (grey bars, n=32), secondary chronic- progressive MS (black bars, 
n=22) and controls (white bars, n=25). Upregulation of Cxcr4 in both patient groups 
compared to controls was observed (*ANOVA, P<0.05). B, CXCL12 serum levels were 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
 
assessed by ELISA in patients with relapsing-remitting MS (grey bars, n=24), secondary 
chronic progressive MS (black bars, n=28) and controls (white bars, n=21). Increased serum 
levels of CXCL12 were measured in both MS groups compared to controls (*ANOVA, 
P<0.05). Quantitative PCR results are expressed as 2-ΔΔ CT values. Numbers are mean +/- 
SEM. 
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Fig. 4. EAE in B6.129P2-Cd38tm1Lnd/J mice.  
A, EAE was induced in female B6.129P2-Cd38tm1Lnd/J mice (open triangles) and C57BL/6J 
000664 controls (closed triangles) with MOG 1-125 in CFA. On day 0 and 2 p.i. mice 
received an i.v. injection of 150 ng pertussis toxin. EAE was scored as follows: 0, no disease; 
1 tail paralysis; 2, paraparesis; 3, paraplegia; 4, tetraparalysis; 5, moribund or dead. 
Immunization with the extracellular domain of MOG, MOG 1-125 lead to disease reduction 
in B6.129P2-Cd38tm1Lnd/J (n=22) compared to C57BL/6J 000664 controls (n=21) mice (t-test, 
cumulative disease score, P=0.01). B, Antibodies against MOG 1-125 were measured by 
ELISA as described (Weissert et al., 2001). B6.129P2-Cd38tm1Lnd/J (white bars, n=4) mice 
had reduced IgG and IgG1 antibodies compared to C57BL/6J 000664 mice (black bars, n=4) 
(*ANOVA, P<0.05) on day 12 p.i. c, T cell responses upon restimulation against MOG 1-125 
from draining lymph nodes on day 12 p.i. were reduced in B6.129P2-Cd38tm1Lnd/J (open 
triangles, n=4) compared to C57BL/6J 000664 (closed triangles, n=4) mice (*t-test for 
stimulation with 50µg/ml MOG 1-125, P=0.05). Numbers are mean +/- SEM. 
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Fig. 5. Influence of FTY720 in EAE.  
A, Female LEW.1AV1 (RT1av1) rats were immunized with MOG 1-125 in CFA. EAE was 
scored as follows: 0, no disease; 1 tail paralysis; 2, paraparesis; 3, paraplegia; 4, 
tetraparalysis; 5, moribund or dead. FTY720 completely inhibited EAE in rats treated orally 
with 0.4 mg/kg from day 0 p.i. (open triangles, n=10) as compared to vehicle (PBS)- treated 
controls (closed triangles, n=10) (t-test, cumulative disease score P<0.0001). B, Female DA 
(RT1av1) rats treated orally with 0.4 mg/kg FTY720 starting on day 21 p.i. after a first bout of 
disease (open triangles, n=8) showed a disease course compared to vehicle (PBS)- treated 
controls (closed triangles, n=8) (t-test, cumulative disease score day 21-44 p.i., P=0.01). On 
day 44 p.i. rats were boosted with MOG 1-125 in CFA. Both groups relapsed but with a 
better outcome of the FTY720 treated group (t-test, cumulative disease score day 45-56 p.i., 
P<0.0001). C, FACS analysis of cells from draining lymph nodes demonstrated an increase 
in relative size of the CD4 T cell compartment and a decrease in the size of the CD8 and B 
cell compartment in FTY720 treated (white bars, n=10) rats compared to controls (black bars, 
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n=9) (*ANOVA, P<0.01) on day 14 p.i.. D, Expression of S1p1 (Edg1), Akt2, Cxcr4 and 
Cd38 was assessed in FTY720 (open bars, n=9) compared to vehicle- treated controls (black 
bars, n=9) by quantitative PCR. FTY720 treatment lead to downregulation of S1p1 and Akt2 
as well as Cd38 but not Cxcr4 (*ANOVA for all except Cxcr4 P< 0.0001) on day 14 p.i. 
from cells derived from lymph nodes. Results are expressed as 2-ΔΔ CT values. Numbers are 
mean +/- SEM. 
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Gene 
Symbol Gene Title Affymetrix Probe Set ID
MOG 91-108 
vs naive 
percentage
MOG 91-108 
vs naive 
average SLR
MOG 91-108 
vs CFA 
percentage
MOG 91-108 
vs CFA 
average SLR
MOG 91-108 
vs MOG73-90 
percentage
MOG 91-108 
vs MOG73-90 
average SLR Function (putative)
Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 M33648_g_at 100 3.27 100 1.39 100 2.15 metabolism
Ptpn16 protein tyrosine phosphatase non-r. type 16 U02553cds_s_at 100 3.22 80 1.87 100 3.00 intracellular signaling
Cxcr4 Chemokine receptor (LCR1) rc_AA945737_at 100 1.94 80 1.48 100 1.67 chemokine receptor
Ccl3 chemokine (C-C motif) ligand 3 U22414_at 90 2.68 70 1.86 60 0.72 chemokine
Jun v-jun sarcoma virus 17 oncogene hom. rc_AI175959_at 80 2.19 100 2.95 60 1.12 intracellular signaling
Cd38 CD38 antigen rc_AA819187_s_at 60 1.75 100 2.62 60 0.98 ectoenzyme cADPR
Max Max D14447_at 50 2.79 60 2.96 100 2.21 cell cycle
Cxcl2 chemokine (C-X-C motif) ligand 2 U45965_at 100 6.63 80 2.21 chemokine
Il1b interleukin 1 beta E01884cds_s_at 100 4.64 60 1.32 chemokine
Cebpb CCAAT/enhancer binding protein (C/EBP), betaS77528cds_s_at 100 4.55 80 2.68 cell cycle
Ass arginosuccinate synthetase X12459_at 100 4.55 60 1.77 metabolism
Arg1 arginase 1 J02720_at 100 4.36 50 1.43 metabolism
Fcgr3 Fc receptor, IgG, low affinity III M32062_g_at 100 4.26 80 1.86 complement receptor
Ptgs2 prostaglandin-endoperoxide synthase 2 S67722_s_at 100 3.95 60 1.96 inflammation
Spp1 secreted phosphoprotein 1 M14656_at 100 3.49 50 1.13 inflammation
Olr1 oxidised low density lipoprotein receptor 1 rc_AI071531_s_at 100 3.37 80 2.04 metabolism
Nos2 nitric oxide synthase 2, inducible U03699complete_seq_at 100 3.19 80 2.71 inflammation
Anpep alanyl (membrane) aminopeptidase M25073_at 100 3.04 50 1.80 metabolism
Vegf vascular endothelial growth factor rc_AA850734_at 100 2.81 50 1.28 growth factor
Igsf6 immunoglobulin superfamily, member 6 AJ223184_at 100 2.73 50 0.85 unknown
F3 coagulation factor 3 U07619_at 100 2.32 70 1.54 coagulation
Edn1 endothelin 1 M64711_at 90 1.85 50 1.06 homeostasis
Wap whey acidic protein J00801_at 60 1.27 90 1.65 milk protein
Junb Jun-B oncogene X54686cds_at 60 1.24 50 0.94 transcription
Anp32a acidic nuclear phosphoprotein 32 family A D32209_at 50 0.84 50 1.11 unknown
LOC286890tropomyosin isoform 6 rc_AA866465_s_at 50 2.02 50 100 3.24 cell structure
Cdkn1b cyclin-dependent kinase inhibitor 1B D83792_at 100 3.20 cell cycle
Hmgb1 high mobility group box 1 rc_AA944177_at 80 1.12 transcription
Smstr28 somatostatin receptor 28 X63574_at 60 1.04 metabolism
Klf9 Kruppel-like factor 9 D12769_at 60 1.01 transcription
Cited2 Cbp/p300-interacting transactivator 2 rc_AA900476_at 90 1.84 transcription
Akt2 murine thymoma (v-akt) oncogene hom. 2 rc_AI105076_s_at 80 1.64 intracellular signaling
Hba1 hemoglobin, alpha 1 X56325mRNA_s_at 60 1.27 metabolism
Zfp36 zinc finger protein 36 X63369cds_at 60 0.93 cell cycle
Sv2b synaptic vesicle glycoprotein 2 b L10362_at 50 1.39 metabolism
Mmp12 matrix metalloproteinase 12 X98517_at 50 1.16 proteases
Hmox1 heme oxygenase  1 J02722cds_at 50 1.13 unknown
Klf4 Kruppel-like factor 4 (gut) L26292_g_at 50 1.05 transcription
Il1a interleukin 1 alpha D00403_g_at 50 0.99 chemokine
Slc2a1 solute carrier family 2,member 1 M13979_at 50 0.87 metabolism
Dcn decorin Z12298cds_s_at 50 0.85 extracellular matrix
Gadd45a growth arrest and DNA-dam.-induc.45a rc_AI070295_g_at 50 0.75 cell cycle  
 
Table 1. Genes with increased expression in lymph node cells of LEW.1AV1 (RT1av1) 
rats 
LEW.1AV1 (RT1av1) rats were immunized with MOG 91-108 in CFA, MOG 73-90 in CFA 
and CFA alone. Gene expression in lymph node cells was analysed using Affymetrix gene 
arrays. Gene arrays from rats immunized with MOG 91-108 in CFA (pooled samples of at 
least n=3 rats, n=5 gene chips) were compared to gene arrays from naive rats (pooled 
samples, n=2 chips), CFA immunized rats (pooled samples, n=2 chips) and MOG 73-90 in 
CFA immunized rats (pooled samples, n=1 chip) resulting in each ten comparisons for CFA 
and naïve to MOG 91-108-immunized rats and five for MOG 73-90 to MOG 91-108-
immunized rats. The number of comparisons in which a given gene had a SLR above 1 were 
counted. If a gene had a SLR above 1 in 50% of the comparisons it was included in the 
analysis. ESTs and sequences not corresponding to a gene and duplicates were removed from 
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the table. Genes which fulfilled the criteria in all of the three comparisons are displayed on 
the top of the table. Genes which fulfilled the criteria only in naive versus MOG 91-108 in 
CFA comparisons are not displayed here. Lymph node cells were prepared as described 
(Weissert et al., 2001).  
